Literature DB >> 16488907

Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome.

Elena Pau1, Isabel Alonso-Muriel, Raul Gómez, Edurne Novella, Amparo Ruiz, Juan A García-Velasco, Carlos Simón, Antonio Pellicer.   

Abstract

BACKGROUND: Ovarian hyperstimulation syndrome (OHSS) is a life-threatening condition associated with ovarian stimulation. Its pathophysiology is unknown and its treatment continues to be empirical. Early (E)- and late (L)-OHSS occur in women at risk, though not in all cases. Vascular endothelial growth factor (VEGF) is related to increased vascular permeability in OHSS. We analysed the dynamics of the VEGF system in E- and L-OHSS.
METHODS: A prospective cohort of women undergoing IVF-ICSI treatment were divided into groups. E-OHSS: Nonpregnant patients classified as women not at risk (group 1) (n = 11) and patients at risk who did not (group 2) (n = 18) and did (group 3) (n = 8) develop severe OHSS. Blood was drawn on the day of ovum retrieval (day 0) and 3, 6, 10 and 14 days later. L-OHSS: Single pregnancies classified as women who did not (group 4) (n = 8) and did develop (group 5) (n = 4) OHSS. Single pregnancies after oocyte donation (OD) (n = 4) were compared with groups 4 and 5 (IVF-ICSI). Blood was obtained weekly (weeks 4-12). Total VEGF (VEFG-A), free (f)-VEGF and soluble VEGF receptor 1 (sVEGFR-1) in plasma and in serum alpha2-macroglobulin (M) were also measured.
RESULTS: Group 3 showed significantly (P < 0.05) higher VEFG-A and f-VEGF than group 1 on day 6 because of lower sVEGFR-1 secretion. Similarly, group 5 had significantly (P < 0.05) more VEFG-A and f-VEGF and less sVEGFR-1 than group 4. Oocyte donation was associated with decreased sVEGFR-1 secretion, and alpha2M was not relevant in OHSS development.
CONCLUSION: In E- and L-OHSS, the ability to secrete sVEGFR-1 and bind VEGF seems to be the determinant factor in OHSS. f-VEGF acts locally in the ovary.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16488907     DOI: 10.1093/humrep/del005

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

1.  Ovarian hyperstimulation syndrome after assisted reproductive technologies: trends, predictors, and pregnancy outcomes.

Authors:  David A Schirmer; Aniket D Kulkarni; Yujia Zhang; Jennifer F Kawwass; Sheree L Boulet; Dmitry M Kissin
Journal:  Fertil Steril       Date:  2020-07-14       Impact factor: 7.329

2.  A unique human chorionic gonadotropin antagonist suppresses ovarian hyperstimulation syndrome in rats.

Authors:  Pratibhasri A Vardhana; Martin A Julius; Susan V Pollak; Evan G Lustbader; Rhonda K Trousdale; Joyce W Lustbader
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

3.  Changes in circulating levels and ratios of angiopoietins during pregnancy but not during the menstrual cycle and controlled ovarian stimulation.

Authors:  Amanda K Hurliman; Leon Speroff; Richard L Stouffer; Phillip E Patton; Annette Lee; Theodore A Molskness
Journal:  Fertil Steril       Date:  2009-05-23       Impact factor: 7.329

4.  Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study.

Authors:  George T Lainas; Efstratios M Kolibianakis; Ioannis A Sfontouris; Ioannis Z Zorzovilis; George K Petsas; Theoni B Tarlatzi; Basil C Tarlatzis; Trifon G Lainas
Journal:  Reprod Biol Endocrinol       Date:  2012-08-31       Impact factor: 5.211

5.  Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulation.

Authors:  Reshef Tal; David B Seifer; Richard V Grazi; Henry E Malter
Journal:  Vasc Cell       Date:  2013-10-24

6.  Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeys.

Authors:  C V Bishop; D M Lee; O D Slayden; X Li
Journal:  J Ovarian Res       Date:  2017-07-06       Impact factor: 4.234

7.  Comparison of follicular fluid and serum levels of Inhibin A and Inhibin B with calculated indices used as predictive markers of Ovarian Hyperstimulation Syndrome in IVF patients.

Authors:  Jiri Moos; Karel Rezabek; Vanda Filova; Martina Moosova; Jana Pavelkova; Jana Peknicova
Journal:  Reprod Biol Endocrinol       Date:  2009-08-24       Impact factor: 5.211

8.  Secretion of soluble vascular endothelial growth factor receptor 1 (sVEGFR1/sFlt1) requires Arf1, Arf6, and Rab11 GTPases.

Authors:  Jae-Joon Jung; Ajit Tiwari; Shivangi M Inamdar; Christie P Thomas; Apollina Goel; Amit Choudhury
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.